RayKnowChina Research Map
Shortlist

RecruitingGliomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma

An open trial on glioma, registered on ClinicalTrials.gov. Led by Tianjin Medical University General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06327451, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 60 years; sex: all

    Registered eligibility fields

  2. According to the 2021 WHO latest classification, the molecular pathology of postoperative glioma samples was diagnosed as WHO 4 glioblastoma;

    Inclusion criterion 3

  3. The immunohistochemical results of postoperative glioma samples showed that EGFR score was 3 (standard: 0 was negative, 1-3 was positive);

    Inclusion criterion 4

  4. patients with a history of HIV and/or HBV/HCV or presence of HIV/HCV;

    Exclusion criterion 11

  5. pregnant or lactating patients;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06327451, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • age ≥18 years old and < 60 years old, both sexes;
  • sufficient evidence of glioma by MRI scan;
  • According to the 2021 WHO latest classification, the molecular pathology of postoperative glioma samples was diagnosed as WHO 4 glioblastoma;
  • The immunohistochemical results of postoperative glioma samples showed that EGFR score was 3 (standard: 0 was negative, 1-3 was positive);
  • normal blood routine and liver function;
  • fully understand the nature of the trial and sign the informed consent;
  • be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures;
  • no serious diseases or accidents requiring surgery;
  • normal immune function.

Exclusion Criteria:

  • allergy to atorvastatin or its components;
  • concomitant use of clarithromycin, itraconazole, ritonavir, saquinavir, lopinavir, cyclosporine, rifampicin, efavirenz, digoxin, warfarin, oral contraceptives;
  • other tumors (except glioma), hematological diseases or other known multiple organ failure, history of myasthenia gravis, heart failure, cerebral hernia and other serious complications;
  • History of cardiac insufficiency, arrhythmia, retinopathy, acute hepatic porphyrin, hepatic and renal insufficiency, obesity, uncontrolled diabetes and other metabolic diseases;
  • abnormal liver function or liver disease, including uncontrolled hepatitis;
  • other diseases that might interfere with the study, as determined by 2 attending neurosurgeons;
  • patients enrolled in a clinical trial within the past 4 weeks;
  • pregnant or lactating patients;
  • patients with poor compliance who could not complete the treatment;
  • other conditions that made the patient ineligible for enrollment as determined by the study investigator;
  • patients with a history of HIV and/or HBV/HCV or presence of HIV/HCV;
  • patients with a history of tuberculosis or known existence of tuberculosis;
  • patients with severe infection or signs/symptoms of infection within 2 weeks before the first dose of study drug;
  • patients who received live attenuated vaccine within 4 weeks before the first dose of study drug;
  • patients with previous solid organ transplantation or hematopoietic stem cell transplantation.

Those who meet any of the above criteria will not be selected.

Quoted from ClinicalTrials.gov, NCT06327451, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06327451, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06327451